4.6 Article

Prognostic value of total testosterone levels in patients with acute coronary syndromes

Journal

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
Volume 28, Issue 2, Pages 235-242

Publisher

OXFORD UNIV PRESS
DOI: 10.1177/2047487319853343

Keywords

Acute coronary syndromes; cardiovascular risk; testosterone; cardiovascular prevention

Funding

  1. Swiss National Science Foundation [SPUM 33CM30-124112, SPUM 33CM30140 336, SNSF 320030-150025, SNSF 32473B_163271, PZ00P3-167826]
  2. Geneva University Hospitals
  3. Swiss Heart Foundation
  4. de Reuter Foundation
  5. Gustave Prevost Foundation
  6. Gerbex-Bourget Foundation
  7. Arthemis Foundation
  8. Leenaards Foundation
  9. Swiss Society of Endocrinology and Diabetes
  10. Roche Diagnostics
  11. Eli Lilly
  12. AstraZeneca
  13. Medtronic
  14. Merck Sharpe and Dome (MSD)
  15. Sanofi-Aventis
  16. St. Jude Medical

Ask authors/readers for more resources

The study found a high prevalence of low total endogenous testosterone levels in men with acute coronary syndromes, but after adjusting for high-risk confounders, low testosterone levels were not significantly associated with mortality.
Background Endogenous testosterone levels decrease in men with aging. Controversies persist regarding the screening and treatment of low testosterone levels in patients with acute coronary syndromes (ACS). Methods and results Total serum testosterone levels were measured in 1054 men hospitalized for ACS that were part of a Swiss prospective cohort. Total testosterone levels were classified first in tertiles and using the cut-off of 300 ng/dL. Primary endpoint was all-cause mortality at one year. Cox regression models adjusting for the GRACE score (composite of age, heart rate systolic blood pressure, creatinine, cardiac arrest at admission, ST segment deviation, abnormal troponin enzyme and Killip classification), preexisting diabetes and inflammation (high-sensitivity C-reactive protein). A total of 430 men (40.8%) had total testosterone levels <= 300 ng/dL. Low total testosterone levels were correlated with lower high-density lipoprotein cholesterol and higher triglycerides, high-sensitivity C-reactive protein, high-sensitivity troponin T, N-terminal-pro B-type natriuretic peptide and glucose levels (all p < 0.01). Patients in the lowest testosterone tertile had a mortality rate at one-year of 5.4% compared with 2.9% in the highest tertile with an unadjusted hazard ratio of 1.92 (95% confidence interval 0.96-1.90, p = 0.095) and adjusted hazard ratio of 1.26 (95% confidence interval 0.57-2.78, p = 0.565). In an exploratory analysis, the highest mortality rate (10.3%) was observed in men aged >65 years old belonging to the lowest testosterone tertile. Conclusion In this large population of men with ACS, we found a prevalence of low total endogenous testosterone levels of almost 40%. However, low testosterone levels were not significantly associated with mortality after adjustment for high-risk confounders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available